PharmaEngine

PharmaEngine EBIT CAGR 3Y

The EBIT CAGR (3 Year) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 2.72 %. In the previous year, EBIT CAGR (3 Year) was 2.72 % — a change of 0.00% (lower).

EBIT CAGR 3Y

2.72 %

YoY

0.00%

Last updated:

EBIT CAGR (3 Year) of PharmaEngine is 2025 2.72 % . EBIT CAGR (3 Year) of PharmaEngine was 2024 2.72 % . It decreases by 0.00% lower compared to the previous year.

The PharmaEngine EBIT CAGR 3Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 3Y
Date
EBIT CAGR 3Y
Jan 1, 2018
2.72 TWD
Jan 1, 2019
2.72 TWD
Jan 1, 2020
2.72 TWD
Jan 1, 2021
2.72 TWD
Jan 1, 2022
2.72 TWD
Jan 1, 2023
2.72 TWD
Jan 1, 2024
2.72 TWD
Jan 1, 2025
2.72 TWD
The PharmaEngine EBIT CAGR 3Y history
YEAREBIT CAGR 3YYoY
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %0.00%
2.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EBIT CAGR (3 Year) of PharmaEngine is 2.72 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (3 Year) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

The 3-year EBIT CAGR shows the compound annual growth rate of EBIT over the past three years.

To evaluate EBIT CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (3 Year).

EBIT CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (3 Year)'s PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — PharmaEngine

All Key Metrics — PharmaEngine